AVITA Medical Inc (AVHHL) reports a 30% revenue increase and unveils promising new products, despite facing challenges in the European market.

Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

The inflation adjustments of TIPS make these securities unique ... Treasury stakes provide a liquidity buffer and typically account for less than 5% of assets; this was about 3.8% of September ...